Dan Werb

PhD

Scientist

Biography

Dan Werb, PhD, is an epidemiologist and policy analyst with expertise in overdose, Human Immunodeficiency Virus (HIV), addictions, and drug policy. Dr. Werb is a Research Scientist at the Li Ka Shing Knowledge Institute (LKSKI) at St. Michael’s Hospital in Toronto. He is also an Assistant Professor in the Division of Infectious Diseases & Global Public Health at the University of California, San Diego. Dr.Werb is Director of the Centre on Drug Policy Evaluation, a recognized global leader in cutting edge policy research and communications. Dr. Werb has published dozens of studies on issues related to health policy and addictions, with a focus on preventing the transition of street youth into injection drug use, as well as on identifying the impact of policy and public health interventions on street-based drug-using populations.

Please note: Dr. Werb is not taking any summer students.

 

Recent Publications

  1. Greenwald, ZR, Bouck, Z, McLean, E, Mason, K, Lettner, B, Broad, J et al.. Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: A cross-sectional analysis. J Viral Hepat. 2023;30 (2):160-171. doi: 10.1111/jvh.13780. PubMed PMID:36461705 .
  2. Delaney, SR, Konforte, D, Stefan, C, Palaty, J, Sun, D, McDonald, K et al.. Drug checking services as a surveillance tool for clinical laboratories: Examining trends in the unregulated fentanyl supply. Clin Biochem. 2023;111 :11-16. doi: 10.1016/j.clinbiochem.2022.11.003. PubMed PMID:36379241 .
  3. Rammohan, I, Bouck, Z, Fusigboye, S, Bowles, J, McDonald, K, Maghsoudi, N et al.. Drug checking use and interest among people who inject drugs in Toronto, Canada. Int J Drug Policy. 2022;107 :103781. doi: 10.1016/j.drugpo.2022.103781. PubMed PMID:35803177 .
  4. Smith, LR, Shumskaia, N, Kurmanalieva, A, Patterson, TL, Werb, D, Blyum, A et al.. Cohort profile: the Kyrgyzstan InterSectional Stigma (KISS) injection drug use cohort study. Harm Reduct J. 2022;19 (1):53. doi: 10.1186/s12954-022-00633-5. PubMed PMID:35614508 PubMed Central PMC9131652.
  5. Lazor, T, Blondal, E, Scheim, A, Cubillos, P, Werb, D, Milloy, MJ et al.. Measurement of public health impacts of cannabis legalization in Canada to reflect policy maker priorities: A rapid scoping review of instruments and content domains. Drug Alcohol Depend. 2022;236 :109463. doi: 10.1016/j.drugalcdep.2022.109463. PubMed PMID:35594643 .
  6. Meyers-Pantele, SA, Mittal, ML, Jain, S, Sun, S, Rammohan, I, Fairbairn, N et al.. The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance. Subst Abuse Treat Prev Policy. 2022;17 (1):39. doi: 10.1186/s13011-022-00470-6. PubMed PMID:35590419 PubMed Central PMC9118611.
  7. Mitra, S, Kolla, G, Bardwell, G, Wang, R, Sniderman, R, Mason, K et al.. Requiring help injecting among people who inject drugs in Toronto, Canada: Characterising the need to address sociodemographic disparities and substance-use specific patterns. Drug Alcohol Rev. 2022;41 (5):1062-1070. doi: 10.1111/dar.13473. PubMed PMID:35577755 .
  8. Scarfone, KM, Maghsoudi, N, McDonald, K, Thompson, H, Stefan, C, Beriault, DR et al.. Emerging synthetic cannabinoids detected by a drug checking service in Toronto, Canada. Clin Toxicol (Phila). 2022;60 (8):979-984. doi: 10.1080/15563650.2022.2069575. PubMed PMID:35546568 .
  9. Garg, R, Kitchen, SA, Men, S, Campbell, TJ, Bozinoff, N, Tadrous, M et al.. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis. Drug Alcohol Depend. 2022;236 :109459. doi: 10.1016/j.drugalcdep.2022.109459. PubMed PMID:35489179 PubMed Central PMC9008980.
  10. Bouck, Z, Scheim, AI, Gomes, T, Ling, V, Caudarella, A, Werb, D et al.. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. Int J Drug Policy. 2022;104 :103680. doi: 10.1016/j.drugpo.2022.103680. PubMed PMID:35447476 PubMed Central PMC9005368.
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Division of Global Public Health, University of California San Diego Director, International Centre for Science in Drug Policy